Arvinas (NASDAQ:ARVN) Trading Down 8.9% – Should You Sell?

Arvinas, Inc. (NASDAQ:ARVN) traded down 8.9% on Tuesday . The company traded as low as $25.50 and last traded at $25.55. 211,055 shares changed hands during trading, a decline of 70% from the average session volume of 713,358 shares. The stock had previously closed at $28.04.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on ARVN. HC Wainwright reiterated a “buy” rating and issued a $87.00 target price on shares of Arvinas in a research note on Thursday, October 31st. Barclays reduced their price objective on shares of Arvinas from $60.00 to $48.00 and set an “overweight” rating for the company in a research report on Wednesday, July 31st. Oppenheimer dropped their target price on shares of Arvinas from $50.00 to $40.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. Wedbush restated an “outperform” rating and set a $57.00 price target on shares of Arvinas in a research report on Tuesday, July 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating on shares of Arvinas in a research note on Monday, September 9th. One research analyst has rated the stock with a hold rating and thirteen have given a buy rating to the company’s stock. Based on data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $60.00.

Arvinas Stock Down 1.7 %

The business’s 50-day simple moving average is $25.82 and its two-hundred day simple moving average is $27.37. The firm has a market capitalization of $1.71 billion, a price-to-earnings ratio of -5.34 and a beta of 1.96.

Arvinas (NASDAQ:ARVN) last issued its quarterly earnings results on Wednesday, October 30th. The company reported ($0.68) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.88) by $0.20. The business had revenue of $102.40 million for the quarter, compared to analysts’ expectations of $60.56 million. During the same quarter last year, the company earned ($1.18) earnings per share. The firm’s revenue for the quarter was up 196.0% on a year-over-year basis. Sell-side analysts anticipate that Arvinas, Inc. will post -3.32 earnings per share for the current year.

Institutional Trading of Arvinas

A number of large investors have recently bought and sold shares of the business. SG Americas Securities LLC boosted its stake in shares of Arvinas by 462.2% in the first quarter. SG Americas Securities LLC now owns 36,297 shares of the company’s stock valued at $1,498,000 after buying an additional 29,841 shares in the last quarter. Swiss National Bank boosted its position in shares of Arvinas by 27.5% in the first quarter. Swiss National Bank now owns 114,100 shares of the company’s stock worth $4,710,000 after acquiring an additional 24,600 shares during the last quarter. Sei Investments Co. grew its stake in shares of Arvinas by 219.4% during the 1st quarter. Sei Investments Co. now owns 24,501 shares of the company’s stock valued at $1,012,000 after buying an additional 16,831 shares during the period. ProShare Advisors LLC increased its holdings in shares of Arvinas by 18.8% during the 1st quarter. ProShare Advisors LLC now owns 13,832 shares of the company’s stock worth $571,000 after buying an additional 2,188 shares during the last quarter. Finally, State Board of Administration of Florida Retirement System raised its position in shares of Arvinas by 18.4% in the 1st quarter. State Board of Administration of Florida Retirement System now owns 16,670 shares of the company’s stock worth $688,000 after buying an additional 2,590 shares during the period. Institutional investors and hedge funds own 95.19% of the company’s stock.

About Arvinas

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.